Clinical Trials in Massachusetts

Showing 4381-4400 of 15,316 trials

Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

NCT04455906

This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermatitis.

Atopic Dermatitis

Boston Children's Hospital111 participantsStarted Nov 2020

Boston, Massachusetts, United States

TERMINATEDPhase 226 miles

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

NCT04006119

This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor. Cemiplimab-rwlc (Libtayo) is an antibody (a kind of human protein) that is being tested to see if it will allow the body's immune system to work against glioblastoma tumors. Libtayo (cemiplimab-rwlc) is currently FDA approved in the United States for metastatic cutaneous cell carcinoma (CSCC), but is not approved in glioblastoma. Cemiplimab-rwlc may help your immune system detect and attack cancer cells. Ad-RTS-hIL-12 and veledimex will be given in combination with cemiplimab-rwlc to enhance the IL-12 mediated effect observed to date. The main purpose of this study is to evaluate the safety and efficacy of a single tumoral injection of Ad-RTS-hIL-12 given with oral veledimex in combination with cemiplimab-rwlc.

Glioblastoma

Alaunos Therapeutics40 participantsStarted Aug 2019

Los Angeles, California, United States • San Francisco, California, United States • Jacksonville, Florida, United States +4 more locations

Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

Find Trials by Condition in Massachusetts

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis

Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes

Evaluation of a Twenty-session Cognitive-behavioral Therapy With Anorexia Nervosa (CBT-20-AN) Among Adults (18+)

Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma

Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis

Early Interventional Treatment for Cancer Pain

A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction

AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics

A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis

Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Tritanium® Primary Acetabular Shell Study

The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease

Hairy Cell Leukemia Patient Data Registry

LITMUS Imaging Study

A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors